国际生殖健康/计划生育杂志

国际生殖健康/计划生育 ›› 2020, Vol. 39 ›› Issue (6): 445-449.

• 论著 •    下一篇

非高龄卵巢功能减退患者血清中抗核抗体、抗心磷脂抗体和抗β2糖蛋白1抗体的检测价值

张园，夏心如，蒋春艳，舒黎，吴畏，高彦，黄洁，冒韵东，刘嘉茵，马翔   

  1. 210029  南京医科大学第一附属医院生殖医学科
  • 收稿日期:2020-05-06 修回日期:2020-08-24 出版日期:2020-11-15 发布日期:2020-11-15
  • 通讯作者: 马翔，E-mail：sxmaxiang@126.com E-mail:sxmaxiang@126.com
  • 基金资助:
    江苏省妇幼保健青年人才项目（FRC201793）；东南大学－南京医科大学联合科研攻关项目（JX102GSP2017DN26）；江苏省科教强卫工程（YXZXB2016001）

Detection of Antinuclear Antibodies, Anticardiolipin Antibodies, and Anti-β2-Glycoprotein 1 Antibodies in Non-Elderly Patients with Diminished Ovarian Reserve

ZHANG Yuan，XIA Xin-ru，JIANG Chun-yan，SHU Li，WU Wei，GAO Yan，HUANG Jie，MAO Yun-dong，LIU Jia-yin，MA Xiang   

  1. Department of Reproductive Medicine，The First Affiliated Hospital of Nanjing Medical University，Nanjing 210029，China
  • Received:2020-05-06 Revised:2020-08-24 Published:2020-11-15 Online:2020-11-15
  • Contact: MA Xiang，E-mail：sxmaxiang@126.com E-mail:sxmaxiang@126.com

PDF (PC)

9976

摘要： 目的：探讨抗核抗体（ANA）、抗心磷脂抗体（aCL）和抗β2糖蛋白1抗体（aβ2GP1）是否可作为非高龄卵巢功能减退（DOR）患者行体外受精/胞浆内单精子注射（IVF/ICSI）前病因筛查的检测指标。方法：收集2018年1月—2019年4月在南京医科大学第一附属医院生殖医学科接受IVF/ICSI助孕的非高龄DOR患者（非高龄DOR组，127例）和因男方因素行IVF/ICSI助孕的女性患者（对照组，82例）为研究对象，收集血清，采用免疫荧光法检测ANA，酶联免疫吸附法检测aCL和aβ2GP1。结果：非高龄DOR组3项抗体中至少1项阳性的总阳性率（24.41%，31/127）高于对照组（12.20%，10/82），差异有统计学意义（P＜0.05）；非高龄DOR组ANA阳性率（3.15%，4/127）虽高于对照组（1.22%，1/82），但差异无统计学意义（P＞0.05）；非高龄DOR组aCL总阳性率（8.66%，11/127）与对照组（6.10%，5/82）比较，差异无统计学意义（P＞0.05）；非高龄DOR组aβ2GP1阳性率（15.75%，20/127）高于对照组（6.10%，5/82），差异有统计学意义（P＜0.05）。结论：非高龄DOR患者aβ2GP1阳性率较高，对非高龄DOR患者推荐在IVF/ICSI助孕前进行血清ANA、aCL和aβ2GP1联合筛查。

关键词: 抗体, 抗核；, 抗体, 抗心脂；, 抗β2糖蛋白1抗体；, 卵巢功能减退；, 酶联免疫吸附测定；, 荧光免疫测定

Abstract: Objective: To investigate whether antinuclear antibody (ANA), anticardiolipin antibody (aCL) and anti-β2-glycoprotein1 antibody (aβ2GP1) can be used as the screening markers in non-elderly patients with diminished ovarian reserve (DOR) before their IVF/ICSI treatment. Methods：From January 2018 to April 2019, 127 non-elderly DOR patients (non-elderly DOR group, 127 cases) and 82 women who were planned to undertake IVF/ICSI treatment due to male factors (control group, 82 cases) were collected as the subjects. Sera ANA was detected by immunofluorescence, aCL and aβ2GP1 antibodies were detected by enzyme-linked immunosorbent assay. Results：The total positive rate of at least one of the three antibodies in the non-elderly DOR group (24.41%, 31/127) was significantly higher than that in the control group (12.20%, 10/82), the difference was statistically significant (P＜0.05). The total positive rate of ANA in the non-elderly DOR group (3.15%, 4/127) was slightly higher than that in the control group (1.22%, 1/82), the difference was not statistically significant (P＞0.05). The difference of the total positive rate of aCL was not significant between the non-elderly DOR group (8.66%, 11/127) and the control group (6.10%, 5/82) (P＞0.05). The total positive rate of aβ2GP1 in the non-elderly DOR group (15.75%, 20/127) was significantly higher than that in the control group (6.10%, 5/82), the difference was statistically significant (P＜0.05). Conclusions：The combined screening of serum ANA, aCL and aβ2GP1 can be recommended for non-elderly patients with diminished ovarian reserve before IVF/ICSI treatment. 

Key words: Antibodies, antinuclear；, Antibodies, anticardiolipin；, Anti-β2-glycoprotein 1 antibody；, Diminished ovarian reserve；, Enzyme-linked immunosorbent assay；, Fluoroimmunoassay